<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078151</url>
  </required_header>
  <id_info>
    <org_study_id>ipromet21</org_study_id>
    <nct_id>NCT05078151</nct_id>
  </id_info>
  <brief_title>Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer</brief_title>
  <acronym>iPROMET</acronym>
  <official_title>A Study to Clinically Qualify Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) in Patients With Metastatic Castration Resistant Prostate Carcinoma With Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vall d'Hebron Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prostate Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III-Investigaci√≥n en Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacio Puigvert</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vall d'Hebron Institute of Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The skeleton is the most frequent organ of distal metastases in prostate cancer, often&#xD;
      representing the only site of metastatic disease. Still, assessment of response and&#xD;
      progression to therapies in bone metastases remains a major unmet need, to aid treatment&#xD;
      switch decisions, detecting primary/secondary resistance and to optimize drug development.&#xD;
      The currently used standard imaging techniques, computed tomography (CT) and bone&#xD;
      scintigraphy (BS), do not depict the true extent of bone metastases and are suboptimal in&#xD;
      capturing biological changes occurring in response to treatment.&#xD;
&#xD;
      This results in treatment switch decisions too often being based on PSA changes, which is&#xD;
      neither a surrogate of survival, nor an optimal response biomarker.Diffusion-weighted imaging&#xD;
      (DWI) is a functional magnetic resonance imaging (MRI) technique that studies the movement of&#xD;
      water molecules within a tissue and provides valuable information about the tissue&#xD;
      microstructure and cellularity. Whole body MRI with DWI is highly accurate for bone&#xD;
      metastases detection, outperforming the standard CT and BS and other imaging techniques when&#xD;
      assessing bone metastases.&#xD;
&#xD;
      The investigators hypothesise that DWI changes are a response biomarker in bone metastases&#xD;
      from metastatic castration resistant prostate cancer (mCRPC); these DWI changes can be&#xD;
      detected as early as after 4 weeks of systemic treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in diffusion-weighted MRI as response biomarker</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Apparent Diffusion Coefficient (ADC) percentage change in responders vs non-responders to systemic treatment in patients with CRPC and bone metastases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early response biomarker identification</measure>
    <time_frame>4 weeks after treatment</time_frame>
    <description>Apparent Diffusion Coefficient (ADC) percentage change in responders vs non-responders to systemic treatment in patients with CRPC and bone metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-tumor heterogenous response evaluation</measure>
    <time_frame>4 and 8 weeks after treatment and at disease progression by standard criteria, on average 1 year</time_frame>
    <description>To use diffusion-weighted MRI for identifying anatomic regions of subclonal resistance to systemic treatment and study tumour evolution.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Metastatic prostate cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive whole-body MRI with diffusion-weighted imaging at baseline and after 4 and 8 weeks of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Whole-Body Diffusion Weighted MRI</intervention_name>
    <description>MRI at baseline, after four and eight weeks of treatment and at disease progression or treatment discontinuation.</description>
    <arm_group_label>Metastatic prostate cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men 18 or over years old.&#xD;
&#xD;
          -  Patients with castration resistant prostate cancer.&#xD;
&#xD;
          -  Evidence of bone metastases by any imaging technique.&#xD;
&#xD;
          -  Patients due to start treatment with abiraterone or enzalutamide. In the exploratory&#xD;
             cohorts, we will include patients due to start treatment with other systemic therapies&#xD;
             for advanced prostate cancer (A-taxanes, B-radiopharmaceuticals, C-other therapies).&#xD;
&#xD;
          -  Written (signed and dated) informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to MRI.&#xD;
&#xD;
          -  Inability of patient to tolerate whole body MRI (e.g. claustrophobia).&#xD;
&#xD;
          -  Patients who have received radiotherapy within the last three months and with no bone&#xD;
             metastases outside the radiotherapy field.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vall d'Hebron Institute of Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Perez-Lopez, MD, PhD</last_name>
      <phone>+34 932543450</phone>
      <phone_ext>8682</phone_ext>
      <email>rperez@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Joan Carles, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joaquin Mateo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael Morales, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Suarez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alonso Garcia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>response biomarker</keyword>
  <keyword>functional imaging</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

